Filipe A Moura, MD, PhD
he/him/his
Assistant ProfessorCards
About
Research
Publications
2026
1217-OR: ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b
KANG Y, BERGMARK B, ALEXANDER V, PROHASKA T, RAN X, MURPHY S, GOODRICH E, MOURA F, ZIMERMAN A, WALDMAN E, WEINLAND J, ZHANG S, XIA S, LI D, TSIMIKAS S, GIUGLIANO R, SABATINE M, MARSTON N. 1217-OR: ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b. Diabetes 2026, 75 DOI: 10.2337/db26-1217-or.Peer-Reviewed Original ResearchRisk of APTIMI Study GroupSevere hypertriglyceridemiaWomen's HospitalStudy groupAcute pancreatitisIonis PharmaceuticalsDaiichi SankyoCore trialRegeneron PharmaceuticalsHigh riskHigher risk of APBaseline riskRisk of pancreatitisBoehringer IngelheimResearch grant supportJanssen Research and DevelopmentAmgen Inc.Placebo Q4WHypertriglyceridemia patientsPrimary endpointBaseline TGSecondary endpointsCME programsInstitutional research grantsBeyond the apnea-hypopnea index: Precision cardiovascular risk stratification in obstructive sleep apnea
Gaffey A, Moura F. Beyond the apnea-hypopnea index: Precision cardiovascular risk stratification in obstructive sleep apnea. American Journal Of Preventive Cardiology 2026, 101690. DOI: 10.1016/j.ajpc.2026.101690.Peer-Reviewed Original ResearchEffects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
Oscarsson J, Huhn M, Jiang Y, Gause‐Nilsson I, Wiviott S, Moura F, Wilding J, Cernea S, Van Gaal L, Cahn A, Bhatt D, Johansson P, Sjöström C. Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis. Diabetes Obesity And Metabolism 2026, 28: 6142-6150. PMID: 42046405, PMCID: PMC13243968, DOI: 10.1111/dom.70820.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseEffects of dapagliflozinFibrosis-4Type 2 diabetesHazard ratioCV deathCV riskPlacebo-controlled phase 3 trialLiver fibrosisBaseline FIB-4 scoreRisk of advanced liver fibrosisRisk of liver fibrosisFIB-4 scoreAdvanced liver fibrosisAtherosclerotic cardiovascular disease riskPhase 3 trialAlanine aminotransferase levelsFibrosis-4 scoreAll-cause deathConfidence intervalsASCVD prevalenceHigher event ratePost Hoc AnalysisPlacebo armPrognostic value26-A-10988-ACC BLUNTED HEART RATE RESPONSE TO REGADENOSON IS ASSOCIATED WITH HIGH RISK BEYOND PET QUANTITATIVE MYOCARDIAL BLOOD FLOW
Oliveira J, Kattan C, Vashist A, Stendahl J, Sadeghi M, Sposito A, Miller E, Sinusas A, Feher A, Moura F. 26-A-10988-ACC BLUNTED HEART RATE RESPONSE TO REGADENOSON IS ASSOCIATED WITH HIGH RISK BEYOND PET QUANTITATIVE MYOCARDIAL BLOOD FLOW. Journal Of The American College Of Cardiology 2026, 87: a936-a937. DOI: 10.1016/j.jacc.2026.02.2307.Peer-Reviewed Original Research26-A-10903-ACC APOLIPOPROTEIN C-III (APOC3) INHIBITION IN PATIENTS WITH VERSUS WITHOUT BASELINE FIBRATE USE
Wang A, Prohaska T, Alexander V, Ran X, Goodrich E, Zimerman A, Moura F, Kang Y, Nordestgaard B, Stroes E, Gaudet D, Badimon L, Tsimikas S, Giugliano R, Sabatine M, Marston N, Bergmark B. 26-A-10903-ACC APOLIPOPROTEIN C-III (APOC3) INHIBITION IN PATIENTS WITH VERSUS WITHOUT BASELINE FIBRATE USE. Journal Of The American College Of Cardiology 2026, 87: a178. DOI: 10.1016/j.jacc.2026.02.443.Peer-Reviewed Original Research26-A-15914-ACC DAPAGLIFLOZIN-INDUCED IMPROVEMENTS IN LEFT VENTRICULAR DIASTOLE, ENDOTHELIAL FUNCTION, AND VASCULAR LOAD ARE RELATED: A RANDOMIZED CLINICAL TRIAL
Kimura-Medorima S, Daniela O, Breder I, Soares A, Oliveira J, Munhoz D, Breder J, Bonilha I, de Carvalho L, Filho O, Wolf V, Silva T, Moura F, Souza J, Nadruz W, Sposito A. 26-A-15914-ACC DAPAGLIFLOZIN-INDUCED IMPROVEMENTS IN LEFT VENTRICULAR DIASTOLE, ENDOTHELIAL FUNCTION, AND VASCULAR LOAD ARE RELATED: A RANDOMIZED CLINICAL TRIAL. Journal Of The American College Of Cardiology 2026, 87: a736. DOI: 10.1016/j.jacc.2026.02.1908.Peer-Reviewed Original ResearchEffect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study
Marston N, Bergmark B, Prohaska T, Moura F, Zimerman A, Alexander V, Kang Y, Weinland J, Ran X, Murphy S, Zhang S, Li D, Banach M, Stroes E, Kiss R, Gaudet D, Vrablik M, Goudev A, Bax J, Budoff M, Foldyna B, Lu M, Tsimikas S, Giugliano R, Sabatine M. Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. Circulation 2026, 153: 1539-1548. PMID: 41910513, DOI: 10.1161/circulationaha.126.080012.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialLipid-Lowering TherapyModerate hypertriglyceridemiaPlaque volumeRemnant cholesterolBaseline coronary computed tomography angiographyNoncalcified coronary plaque volumeCoronary atherosclerosisCoronary computed tomography angiography studiesImaging studiesCoronary Computed Tomography AngiographyCoronary plaque volumeBaseline to monthNoncalcified plaque volumeLow-density lipoprotein) cholesterolTriglyceride-rich lipoproteinsBaseline triglyceridesApolipoprotein C-IIIMedian ageNo significant differenceAngiography studiesLDL-CLDL-C.PlaceboCholesterol loweringDOTA-based perfusion imaging in hybrid positron emission tomography/magnetic resonance: Promise, limits, and the importance of tracer kinetics
Moura F, Sinusas A. DOTA-based perfusion imaging in hybrid positron emission tomography/magnetic resonance: Promise, limits, and the importance of tracer kinetics. Journal Of Nuclear Cardiology 2026, 59: 102703. PMID: 41905549, DOI: 10.1016/j.nuclcard.2026.102703.Peer-Reviewed Original ResearchDapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial
Kimura-Medorima S, Oliveira D, Breder I, Wolf V, Soares A, Barreto J, Munhoz D, Cunha J, Bonilha I, de Carvalho L, Coelho-Filho O, Matos-Souza J, Moura F, Nadruz W, Quinaglia T, Sposito A. Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial. Cardiovascular Diabetology 2026, 25: 140. PMID: 41888924, PMCID: PMC13141266, DOI: 10.1186/s12933-026-03142-y.Peer-Reviewed Original ResearchMeSH KeywordsAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrachial ArteryDiabetes Mellitus, Type 2DiastoleEndothelium, VascularFemaleGlucosidesGlyburideHumansMaleMetforminMiddle AgedNitric OxideProspective StudiesRecovery of FunctionSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVascular ResistanceVascular StiffnessVasodilationVentricular Dysfunction, LeftVentricular Function, LeftConceptsFlow-mediated dilationActive-controlled trialSystemic vascular resistanceEndothelial functionVascular resistanceLeft ventricular diastolic function parametersResistance indexBrachial artery resistance indexBrachial artery flow-mediated dilationEchocardiographic diastolic parametersLV diastolic functionArtery flow-mediated dilationDiastolic function parametersArterial impedanceArtery resistance indexTrial of patientsMarker of arterial stiffnessLeft ventricular diastolicAssociated with more favorable changesNitric oxideEndothelial function assessmentRandomized clinical trialsArterial loadType 2 diabetesE/e' ratioA Multicenter Randomized Clinical Trial of Dapagliflozin in Patients Receiving Chronic Dialysis (The DARE-ESKD-2 Trial)
Barreto J, Martins M, Silva C, Jesus D, Baldini M, Oliveira A, da Silva Quadros K, Carbonara C, Silva G, Campos-Staffico A, Zimerman A, Moura F, Coelho-Filho O, Matos-Souza J, Assato B, Bonilha I, Gomes E, Kimura-Medorima S, Nadruz W, Oliveira R, Sposito A. A Multicenter Randomized Clinical Trial of Dapagliflozin in Patients Receiving Chronic Dialysis (The DARE-ESKD-2 Trial). Kidney International Reports 2026, 11: 106355. PMID: 41970273, PMCID: PMC13069122, DOI: 10.1016/j.ekir.2026.106355.Peer-Reviewed Original ResearchMulticenter Randomized Clinical TrialClinical summary scoreKansas City Cardiomyopathy QuestionnaireChronic kidney diseaseNT-proBNPChronic dialysisEchocardiographic measurementsSurrogate markerKansas City Cardiomyopathy Questionnaire clinical summary scoreHeart failureMaintenance dialysisN-terminal pro-brain natriuretic peptideIntergroup differencesStudy armsEnd pointsPro-brain natriuretic peptideSummary scoreSecondary end pointsKCCQ clinical summary scoreStandard careSafety end pointNT-proBNP changesMarkers of HFProportion of patientsNo difference
Academic Achievements & Community Involvement
Teaching & Mentoring
Mentoring
Ray Portela
Internal medical resident2026 - PresentJoaquim Barreto
Graduate student2025 - PresentAnderson Woite, MD
Yale Internal Medicine Resident2025 - PresentAlleh Nogueira
Postgrad associate2024 - Present